Raphael Stevens

Eli Lilly said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial.
Eli Lilly’s pill, orforglipron, is one step closer to becoming the first needle-free alternative in the booming market for weight loss and diabetes drugs called GLP-1s. 
Some doctors lauded the weight loss results, while others made note of the rates of patients at the highest dose of the pill who discontinued treatment due to side effects.

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.
Scott Olson | Getty Images

Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial, paving the way for its entrance into the market.
The pill’s weight loss was 11.2% when analyzing all patients regardless of discontinuations.

Shares of the company fell more than 7% in premarket trading on Thursday. Meanwhile, shares of rival Novo Nordisk, which is also working to bring an obesity pill to the market, jumped more than 7% on Thursday.
The data comes under what some Wall Street analysts were expecting for Eli Lilly’s oral GLP-1, with hopes for weight loss of around 15%. Some doctors said the results appear to be comparable to, but overall slightly lower, the level of weight loss seen with Novo Nordisk’s blockbuster weekly GLP-1 injection for obesity, Wegovy.
Some doctors also made note of the number of patients on the highest dose of the pill who discontinued treatment due to side effects or any other reason in the trial.
Still, other doctors lauded the results and the potential of the pill to reach new patients, such as those who are afraid of needles. 
“This is a strong and promising result for an oral agent,” said Dr. Jaime Almandoz, medical director of the Weight Wellness Program at UT Southwestern Medical Center, calling the weight loss “a significant and clinically meaningful outcome.”

“Injectables have set a high bar, but this study reinforces the potential for an oral GLP-1 to be transformative in obesity care, particularly for patients who are hesitant to start or maintain injectable therapies,” he continued. 
Dr. Mihail “Misha” Zilbermint, director of Endocrine Hospitalists at Johns Hopkins Community Physicians, said he believes the pill “has the potential to be a game changer, as long as people can tolerate the side effects.”
The trial results are among the pharmaceutical industry’s most closely watched studies of the year, and follow positive data in April from a phase 3 trial examining the experimental pill in diabetes patients. They bring Eli Lilly’s pill, orforglipron, one step closer to potentially becoming a new, needle-free alternative without dietary restrictions in the booming market for weight loss and diabetes drugs called GLP-1s. 
Eli Lilly is “not disappointed with these results. It’s right on thesis for us,” despite being “one or two points below what the Street had,” CEO David Ricks told CNBC’s “Squawk Box” on Thursday.
“The goal was to create an oral pill that was convenient and can be made at a huge scale, really, for the mass market, and had weight loss that was competitive with other single-acting GLP-1s, and that’s what we’ve achieved,” Ricks said. He added that the pill’s percentage of weight loss is “in the range” of what most people who are overweight or want to improve their metabolic health want to achieve.

Ricks said Eli Lilly expects to submit the data to regulators by the end of the year, with hopes of launching the pill around the world “this time next year.”
That launch could fundamentally shift the space, helping more patients access the treatments and alleviating the supply shortfalls of existing injections. The more convenient and easier-to-manufacture pill could also help Eli Lilly solidify its dominance in the growing segment as other drugmakers, including its main rival Novo Nordisk, race to bring weight loss pills to market. 
There are roughly 8 million patients on injectable obesity and diabetes drugs, but likely around 170 million who could benefit from the medicines, said Ken Custer, president of Lilly Cardiometabolic Health, in an interview.
“In order to meet that demand, we’re going to need other options, including oral small molecules like orforglipron, which use different means of production and also don’t need as sophisticated of a supply chain to distribute it to patients,” he said.
Dr. Amy Sheer, professor of medicine and program director of the Obesity Medicine Fellowship at the University of Florida, said she hopes the pill will be less expensive than existing injections, which are costly largely due to the devices they come in. She said lower prices could help eliminate barriers to access for patients, potentially making insurers more willing to cover the drug. 
Many insurers still don’t cover GLP-1s for obesity. Wegovy and other drugs have list prices of roughly $1,000 before insurance. 

Detailed trial results

The highest dose of Eli Lilly’s pill helped more than 59% of patients lose at least 10% of their body weight and more than 39% of patients lose at least 15% of their weight, according to the trial results. 
Almandoz said the proportion of people who achieved “greater magnitudes” of weight loss was “very impressive for an oral agent,” adding that many people “often overlook the proportion of people achieving these high weight loss categories” and typically focus closely on the average weight loss
Orforglipron also helped lessen cardiovascular risk factors.
But data on how well some patients tolerated the pill in the trial came under some analysts’ estimates. 
About 10.3% of patients who took the highest dose of the pill — 36 milligrams — discontinued treatment due to side effects, compared with around 2.6% of those who took a placebo. Those side effects were mainly gastrointestinal, such as nausea and vomiting, and mild to moderate in severity. An estimated 24% of those who took the highest dose experienced vomiting, while 33.7% and 23.1% had nausea and diarrhea, respectively.
Ahead of the data, BMO Capital Markets analyst Evan Seigerman said he expected less than 10% of patients on the highest dose of the pill to discontinue treatment due to side effects and lower rates of vomiting, nausea and diarrhea.
More patients stopped taking the pill due to side effects compared with existing GLP-1s on the market, said Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital. The discontinuation rates due to side effects in late-stage trials on Wegovy and Eli Lilly’s weekly obesity injection Zepbound are around 7% or less.
She noted that almost a quarter of patients on the highest dose of the pill discontinued treatment for any reason, cautioning that the enthusiasm for orforglipron should be tempered “because we get all this excitement, and then the pill comes out, and then nobody can take it.”
It’s unclear why, apart from side effects, those patients discontinued the pill. Nearly 30% of those on a placebo discontinued treatment for any reason.
Eli Lilly’s Ricks said the company is not concerned about those dropout rates in the study.
“What we really want to see is that the medicine dropout rate is lower than placebo, and that’s what we saw here,” he said, referring to the discontinuation rates for any reason.
Ricks added that Eli Lilly was looking for a less than 12% dropout rate due to side effects, noting that the industry has seen 8% to 12% rates with GLP-1 drugs.
“We’re right in the middle,” he said. “Continuation rates in this category, in all chronic drug categories, are not perfect. But the dropout from the drug is what we pay attention to, and here again, we’re right on with the profile.”
The University of Florida’s Sheer said she doesn’t believe the discontinuation rates or side effects will be a deciding factor for physicians when prescribing the pill. 
She believes an oral option could actually make more physicians more comfortable prescribing a GLP-1 to patients. Some physicians are currently hesitant to prescribe injections because they “may not know how to tell patients how to use them,” Sheer added. 
Almandoz said prescribing decisions are going to depend on the patient’s specific needs and preferences, as well as access and affordability. An injectable GLP-1 may be the preferred option for patients whose priority is a greater level of weight loss or those who have significant cardiometabolic complications, or health issues that arise from cardiovascular diseases and metabolic disorders. 
But an oral GLP-1 could be the best fit for those who “prioritize simplicity or convenience or have these logistical challenges with injections,” he said.
The detailed results from the trial will be presented in September at a European medical meeting and published in a peer-reviewed journal. More phase three trial results on the pill will be shared later this year, including from a study on adults who have obesity or are overweight and have Type 2 diabetes.
Wegovy, Eli Lilly’s pill, orforglipron and Novo Nordisk’s diabetes pill Rybelsus all work by targeting a gut hormone called GLP-1 to promote weight loss and regulate blood sugar. But unlike those other medications, Eli Lilly’s pill is not a peptide medication. That means it is absorbed more easily in the body and doesn’t require dietary restrictions like Rybelsus does.
Eli Lilly is currently about three years ahead of other drugmakers developing pills, including Pfizer, AstraZeneca, Roche, Structure Therapeutics and Viking Therapeutics, Guggenheim analyst Seamus Fernandez previously CNBC.
Some analysts expect the market for GLP-1s to be worth more than $150 billion annually by the early 2030s. Oral GLP-1s could grow to be worth $50 billion of that total, Fernandez said.
— CNBC’s Angelica Peebles contributed to this report.

Don’t miss these insights from CNBC PRO More

American is adding seasonal service to Budapest, Prague and Buenos Aires for next summer.
Many of American’s summer routes were discontinued because of the Covid-19 pandemic.
Flights are mostly leaving from its hubs in Dallas Fort Worth International Airport and Philadelphia International Airport.

An American Airlines Boeing 787-9 Dreamliner lands at the Miami International Airport on December 10, 2021 in Miami, Florida.
Joe Raedle | Getty Images

American Airlines is reviving some of its pre-pandemic destinations like Prague and Budapest, Hungary, as international travel continues to hold up better than domestic demand.
Other additions include its first-ever Dallas Fort Worth International flights to Athens, Greece, and year-round nonstop service between Miami and Milan.

American is also extending service for next year’s World Cup, from Buenos Aires, Argentina, to Dallas and between Dallas and Zurich, where soccer’s governing body, FIFA, is based,. Those flights will run from May 21 to Aug. 4 of next year, a bid for more business travel and sports tourism.
Brian Znotins, American’s senior vice president of network and schedule planning, told CNBC that the airline saw high numbers of customers from Argentina travel to Doha, Qatar, during the 2022 World Cup and that he expects even more to travel to the 2026 World Cup, which will be played in Canada, the U.S. and Mexico.
He also said the airline is expanding its Europe service in a bet that customers would rather connect in a U.S. hub like Dallas or Charlotte, North Carolina.
“We took a fresh look at where the demand hotspots are in Europe and we continue to see strength in Italy and Greece,” Znotins said. “We continue to see high numbers of travelers connecting in Europe to get to places like Rome and Athens,” so the airline is adding more options from U.S. hubs.

Read more CNBC airline news

With Prague and Budapest service from American’s hub at Philadelphia International Airport, he said many customers already fly into one city and out of the other for Danube River cruises and other tours.

American’s unit revenue for domestic flights in the last quarter fell 6.4% from 2024, while trans-Atlantic revenue rose 5%.
Many of American’s summer routes were discontinued because of the Covid-19 pandemic, but Znotins said the changes weren’t just a return to that period.
“We’ve redesigned the entire airline based on today’s demand environment and not some desire to get back to 2019,” he said. “Everything has changed.”
American will use Boeing 787-8 Dreamliners for all the new flights except for Zurich to Dallas, which will be flown by Boeing 777-200s. More

Craveworthy Brands is now investor and managing partner of Gregorys Coffee.
Craveworthy Brands has been a prolific restaurant investor since its founding in 2022.
Under its stewardship, New York City-based Gregorys plans to expand nationwide by franchising its locations.

Gregorys Coffee was founded in 2006 and has more than 50 locations.
Source: Gregorys Coffee

Craveworthy Brands is now investor and managing partner of Gregorys Coffee, a New York City-based coffee chain with dreams of a nationwide footprint.
The two companies announced the deal on Thursday. Financial terms were not disclosed.

Craveworthy Brands, a fast-growing restaurant holding company, has become a prolific investor since its founding in 2022. Its portfolio includes legacy chains such as Genghis Grill and BD’s Mongolian Grill, emerging concepts including Shaquille O’Neal’s Big Chicken as well as several virtual brands that only offer delivery.
Gregorys was founded in 2006. The regional coffee chain is often counted as part of the third-wave coffee trend that focused on quality beans and artisanal craft, along with peers Blue Bottle Coffee and Intelligentsia Coffee. Today, Gregorys has more than 50 locations, but the deal with Craveworthy Brands is meant to help franchise Gregorys and expand beyond its tristate stronghold.
Founder Gregory Zamfotis will stay on as president of the brand.
“Gregory has built something special: a cult following, a craft product and a clear identity. Our role is to protect that, while layering in the operational firepower to grow thoughtfully,” Craveworthy Brands founder and CEO Gregg Majewski said in a statement.
More than two decades ago, Majewski served as CEO of sandwich chain Jimmy John’s, growing it from a couple dozen restaurants to 300 locations by the time he left in 2003. With Craveworthy Brands, he is looking to build a restaurant IP company, similar to the early days of private equity firm Roark Capital, he told CNBC in an interview in May. Roark owns Subway, Dunkin’ parent Inspire Brands and Cinnabon owner GoTo Foods.

When looking for potential additions to Craveworthy Brands’ portfolio, Majewski has said he’s targeting brands with fewer than 75 locations and the ability to franchise easily. Today, the company’s holdings include more than a dozen eateries, and its investments range from outright ownership to controlling stakes. With the Gregorys acquisition, the company’s annual system sales will cross $400 million, a spokesperson said.
Craveworthy Brands’ latest deal comes as beverages increasingly drive traffic in the restaurant industry. Although Starbucks sales are slumping, newer chains such as Dutch Bros and 7 Brew have seen growth soar in recent years. Fast-food chains such as McDonald’s and Yum Brands-owned Taco Bell are testing broader drink menus, with options to customize and more ways to caffeinate, from refreshers to flavored cold brew.
Harborfield Management, Branded Hospitality and restaurant-focused venture capital firm Kitchen Fund also invested in Gregorys as part of the funding round. Like Majewski and Zamfotis, Kitchen Fund’s managing partner also happens to be named Greg.

Don’t miss these insights from CNBC PRO More

Warner Bros. Discovery’s second-quarter earnings received a boost from its film studios segment following recent periods of underperformance.
Film releases from Warner Bros. Motion Pictures included “A Minecraft Movie,” “Sinners,” “Final Destination: Bloodlines,” and “F1,” which the company said together so far generated over $2 billion.
The company will split into two companies next year, separating the streaming and studios from the global TV networks business.

A still from the film F1 starring Brad Pitt.
Source: F1 | Apple Studios

Warner Bros. Discovery’s earnings got a boost from its film studios after a handful of box office hits during the second quarter.
The period from April though June saw the releases of “A Minecraft Movie,” “Sinners,” “Final Destination: Bloodlines,” and “F1,” which together generated $2 billion in the global box office to date, the company said Thursday.

WBD reported total revenue for the studios segment — which also includes distributing TV content — increased 55% during the quarter to $3.8 billion, with theatrical revenue up 38%, excluding the impact of foreign currency exchange, due to the higher box office revenue.
Adjusted earnings before interest, taxes, depreciation and amortization, or EBITDA, for the studios segment was $863 million during the period, up from $210 million during the same period a year prior.
In a letter to shareholders, WBD said it expects the momentum to continue, with the studios segment projected to generate at least $2.4 billion of adjusted EBITDA for the full year. The company said it was “a substantial step toward” its goal of eventually notching more than $3 billion in adjusted EBITDA for the segment.
While “Superman” was released shortly after the close of the second quarter, the film’s success is likely to help lift the third quarter for Warner Bros. Discovery. “Superman” generated $220 million globally during its opening weekend, which the company said was the “strongest ever debut for a solo Superman film.”
In late July, “Superman” and Apple’s “F1,” which Warner Bros. distributed, had more than $500 million in ticket sales, CNBC reported.

Executives have been in the process of rebuilding Warner Bros. Motion Pictures for several quarters now.
In particular, CEO David Zaslav has called out the need to revive the studios since the merger of Warner Bros. and Discovery in 2022. The segment had been plagued by the closure of theaters at the height of stay-at-home orders during the pandemic, followed by a Hollywood shutdown during the actors’ and workers’ labor strikes in 2023.
To help the unit, the company hired James Gunn and Peter Safran in 2022 as the co-heads of its DC Comics film and TV unit, in a move to steady the ship of the superhero film division. That same year, Warner Bros. appointed Michael De Luca and Pam Abdy as co-heads of Warner Bros. Motion Pictures, each of which had previously led MGM Studios. 
“We’ve had an extraordinary run. You know we were in last place,” said Zaslav on Thursday, noting the studios’ hires shortly after the merger. “And together we went from last to first. You know, Disney is a little bit ahead right now … But we’re really making the turn.” 
Since the merger, Zaslav has said WBD would lean on its library of franchises, including “Lord of the Rings” and “Harry Potter.” On Thursday, Zaslav said the company had the goal of two or three so-called tentpole releases a year, “which provide real stability.”
Zaslav also said the company has already “got a great script” for the upcoming “Lord of the Rings” installment from director Peter Jackson. He also noted the next iteration of the “Superman,” or the “Super family,” franchise is in the works for DC Studios.
Still, the division has been faced with staff cuts, much like the rest of WBD since the 2022 merger. Last month Warner Bros. Motion Picture Group told employees it would cut 10% of its workforce, Deadline reported.
The company is also in the midst of splitting itself apart and essentially undoing the merger of just three years ago. Next year, the present day company will be divided into two units — Warner Bros., comprised of the studios and streaming platform HBO Max; and Discovery Global, made up of the TV networks, Discovery+ and sports business.
Overall, WBD’s total revenue increased 1% during the second quarter to $9.81 billion. Adjusted EBITDA rose 9% to $1.95 billion More

Restaurant Brands International on Thursday reported mixed quarterly results.
Popeyes reported same-store sales declines.
There was strong demand internationally and at Tim Hortons.

A Burger King restaurant with the slogan ”Flame Grilling Since 1954” is seen in Vienna, Austria, on June 7, 2025.
Michael Nguyen | NurPhoto | Getty Images

Restaurant Brands International on Thursday reported mixed quarterly results, as same-store sales declines for Popeyes were offset by strong demand internationally and at Tim Hortons.
Here’s what the company reported for the period ended June 30 compared with what Wall Street was expecting, based on a survey of analysts by LSEG:

Earnings per share: 94 cents adjusted vs. 97 cents expected
Revenue: $2.41 billion vs. $2.32 billion expected

Restaurant Brands reported second-quarter net income attributable to shareholders of $189 million, or 57 cents per share, down from $280 million, or 88 cents per share, a year earlier.
Excluding transaction costs from its acquisition of Burger King China and other one-time costs, the company earned 94 cents per share.
Net sales climbed 16% to $2.41 billion.
The company’s same-store sales, which only tracks the metric at restaurants open at least a year, rose 2.4% during the quarter.
CEO Josh Kobza told CNBC that Restaurant Brands has seen a “modest improvement” in the consumer environment compared to the first quarter, when the company’s three largest brands saw same-store sales decline.

This quarter, Restaurant Brands’ international restaurants reported same-store sales growth of 4.2%.
Tim Hortons, which accounts for more than 40% of Restaurant Brands’ total revenue, reported same-store sales growth of 3.4%.
Burger King reported same-store sales growth of 1.3%. Its U.S. division, which has been in turnaround mode for nearly three years, saw same-store sales increase by 1.5%. More than half of its U.S. restaurants have been renovated since the turnaround began; the burger chain aims to have 85% of its U.S. footprint upgraded by 2028.
Popeyes was the laggard of the portfolio for the most recent quarter, reporting same-store sales declines of 1.4%. But the fried chicken chain’s results have improved compared with the first three months of the year, when its same-store sales slid 4%. To lift sales in the second half of the year, Popeyes has a “bunch of innovation” on its schedule, Kobza said.
For the full year, Restaurant Brands reiterated its forecast, anticipating that it will spend between $400 million and $450 million on consolidated capital expenditures, tenant inducements and other incentives. The company also said that it still expects to reach its long-term algorithm, which projects 3% same-store sales growth and 8% organic adjusted operating income growth on average between 2024 and 2028.
This story is developing. Please check back for updates. More

In the past year, U.S. companies made more progress in getting employees back to the office than at any time since 2020, according to a forthcoming report from CBRE.
Nearly three quarters of the 184 companies surveyed by CBRE said they have met their attendance goals, up from 61% last year.
More companies said they expect to expand their office footprints, rather than contract, according to the survey.

Maskot | Digitalvision | Getty Images

A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight to your inbox.
In the past year, U.S. companies made more progress in getting employees back to the office than at any time since 2020, when the pandemic fundamentally changed the traditional work paradigm. This is according to a forthcoming report from CBRE, due out next week. While some employers have gone fully remote and some offer hybrid work opportunities, the push is on to get more workers back to the office.

Nearly three quarters of the 184 companies surveyed by CBRE said they have met their attendance goals, up from 61% last year. The share of companies monitoring attendance jumped to 69% this year from 45% last year, and those enforcing attendance policies rose to 37% from 17%. Companies in the survey said they want employees in the office an average of 3.2 days a week. Actual attendance, however, is slightly below that. 
“I think it was pretty loosey goosey for the last year or two, and I think the companies have got a lot better at that right now,” said Manish Kashyap, CBRE’s global president of leasing. “They’re coming up with policies that allow hybrid structures and allow flexibility, but whatever their new policy is, their implementation around that, and the governance around that, is definitely a lot better.”

Get Property Play directly to your inbox

CNBC’s Property Play with Diana Olick covers new and evolving opportunities for the real estate investor, delivered weekly to your inbox.
Subscribe here to get access today.

More companies said they expect to expand their office footprints, rather than contract, according to the survey. Over the past several years there has been a huge slowdown in office development and a surge in conversions to residential. 
The majority of survey respondents, 67% of companies, said they will either keep their office footprints at the same size or expand them within the next three years, up from 64% a year ago. For expansion, most pointed to business or headcount growth. About a third said they will reduce their space, down from 36% last year and 53% in 2023.
Concerns about the economy and tariffs do have some companies hesitating to make long-term decisions, but even with that concern, more are taking on long-term leases than were a year ago, CBRE found. 

“You have organizations that finally have clarity and decision making, because they’ve been living in this world of hybrid for so long, and now they know what it truly looks like for them, so all those decisions that they may have put off, even if there’s a little bit of economic uncertainty right now, they’re still willing to move forward with some additional deals,” said Julie Whelan, CBRE’s global head of occupier research.
Despite the fact that overall office vacancies are at 18.9%, just under the 30-year high of 19%, nearly half of the companies surveyed said they were concerned about the availability of high-quality office space over the next three years. That concern is most significant when it comes to prime space, which accounts for only 8% of the total office inventory and has much lower vacancy rate than the rest of the market. 
“For many, office footprints now are smaller but more effective and better tailored for collaborative work. Employers are much more focused now than they were pre-pandemic on quality of workplace experience, the efficiency of seat sharing and the vibrancy of the districts in which they’re located,” said Whelan. More

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.
Eli Lilly also released long-awaited late-stage trial data on its experimental obesity pill, orforglipron, the highest dose of which helped patients lose more than 12% of their body weight.

The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, on Sept. 17, 2020.
Mike Blake | Reuters

Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.
The company raised its fiscal 2025 sales guidance to $60 billion to $62 billion, from a previous outlook of $58 billion to $61 billion on underlying strength across its business. The pharmaceutical giant also expects its adjusted fiscal 2025 earnings to come in between $21.75 to $23, up from a previous guidance of $20.78 and $22.28 per share. 

Eli Lilly said the guidance reflects President Donald Trump’s existing tariffs as of Aug. 7, but does not include his planned levies on pharmaceuticals imported into the U.S.
Also on Thursday, Eli Lilly released long-awaited late-stage trial data on its experimental obesity pill, orforglipron, the highest dose of which helped patients lose more than 12% of their body weight. That came under Wall Street’s expectations, sending shares down as much as 12% in premarket trading on Thursday.
“I feel good about the value of the company. Investors have to decide what they think,” Eli Lilly CEO David Ricks told CNBC’s “Squawk Box.” “But Lilly is rolling, and you look at the beat and raise, strong growth on the back half, we’re excited about the future for our company and for patients who need our products.”
The company’s diabetes treatment Mounjaro topped expectations for the first quarter, raking in almost $5.2 billion in revenue. That’s up 68% from the same period a year ago.
Eli Lilly’s weight loss drug Zepbound also beat estimates, booking $3.38 billion in sales for the quarter, up a whopping 172% from the year-earlier period. 

Analysts had expected Mounjaro and Zepbound to generate $4.49 billion and $3.06 billion in sales, respectively, according to estimates from StreetAccount.
“Tirzepatide, which is Mounjaro and Zepbound, will likely become the best-selling drug in the industry in its third year in the market,” Ricks told CNBC. “And we’ve got a lot more coming in the pipeline.”
Here’s what Eli Lilly reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

Earnings per share: $6.31 adjusted vs. $5.57 expected
Revenue: $15.56 billion vs. $14.71 billion expected

The company posted second-quarter revenue of $15.56 billion, up 38% from the same period a year ago. 
Sales in the U.S. jumped 38% to $10.81 billion. Eli Lilly said that was driven by a 46% increase in volume — or the number of prescriptions or units sold — for its products, primarily for Mounjaro and Zepbound. That was partially offset by lower realized prices of the drugs, the company said.
The pharmaceutical giant booked net income of $5.66 billion, or $6.29 per share, for the second quarter. That compares with net income of $2.97 billion, or $3.28 per share, a year earlier. 
Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted earnings of $6.31 per share for the second quarter.
The results also come as Eli Lilly and other drugmakers brace for levies on pharmaceuticals imported into the U.S. and face his calls to lower drug prices in the country.
The president sent letters to Eli Lilly and other companies last week calling on them take steps to lower drug prices by Sept. 29. The move came after Trump in May signed an executive order reviving a controversial plan, the “most favored nation” policy, that aims to slash drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad. More